应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06660 艾美疫苗
耶稣受难节休市 03-28 16:08:03
8.130
+0.120
+1.50%
最高
8.300
最低
7.970
成交量
27.46万
今开
8.150
昨收
8.010
日振幅
4.12%
总市值
98.46亿
流通市值
40.01亿
总股本
12.11亿
成交额
221.87万
换手率
0.06%
流通股本
4.92亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
艾美疫苗近年来研发投入呈高速增长态势 2024年三款重磅迭代升级疫苗申报上市
经济参考网 · 03-28 14:32
艾美疫苗近年来研发投入呈高速增长态势 2024年三款重磅迭代升级疫苗申报上市
艾美疫苗(06660.HK)提交两项流感疫苗临床试验预申请
阿斯达克财经 · 03-28 10:28
艾美疫苗(06660.HK)提交两项流感疫苗临床试验预申请
艾美疫苗(06660):2023年业绩超预期,多款疫苗即将申报上市
和讯网 · 03-28 09:13
艾美疫苗(06660):2023年业绩超预期,多款疫苗即将申报上市
艾美疫苗今年三款重磅迭代升级疫苗申报上市,国际市场布局业已展开
格隆汇资讯 · 03-28 08:24
艾美疫苗今年三款重磅迭代升级疫苗申报上市,国际市场布局业已展开
艾美疫苗(06660):四价MDCK细胞流感病毒疫苗提交临床试验预申请
智通财经 · 03-28 08:13
艾美疫苗(06660):四价MDCK细胞流感病毒疫苗提交临床试验预申请
艾美疫苗(06660)已提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请
智通财经 · 03-28 08:12
艾美疫苗(06660)已提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请
艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗
智通财经 · 03-28 08:04
艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗
艾美疫苗(06660):新型工艺高效价人二倍体狂犬病疫苗提交临床试验预申请
智通财经 · 03-26 21:23
艾美疫苗(06660):新型工艺高效价人二倍体狂犬病疫苗提交临床试验预申请
艾美疫苗(06660)上涨5.04%,报8.96元/股
金融界 · 03-21
艾美疫苗(06660)上涨5.04%,报8.96元/股
艾美疫苗盘中异动 股价大涨5.29%
自选股智能写手 · 03-21
艾美疫苗盘中异动 股价大涨5.29%
艾美疫苗03月19日获主力加仓117万元 环比增加408.70%
自选股智能写手 · 03-19
艾美疫苗03月19日获主力加仓117万元 环比增加408.70%
艾美疫苗03月18日主力资金流入23万元 连续5日加仓
自选股智能写手 · 03-18
艾美疫苗03月18日主力资金流入23万元 连续5日加仓
艾美疫苗(06660.HK)3月27日举行董事会会议考虑及批准年度业绩
格隆汇资讯 · 03-15
艾美疫苗(06660.HK)3月27日举行董事会会议考虑及批准年度业绩
艾美疫苗03月14日获主力加仓132万元 环比增加1100.00%
自选股智能写手 · 03-14
艾美疫苗03月14日获主力加仓132万元 环比增加1100.00%
艾美疫苗(06660)下跌5.33%,报8.0元/股
金融界 · 03-13
艾美疫苗(06660)下跌5.33%,报8.0元/股
艾美疫苗盘中异动 股价大涨5.08%报8.280港元
自选股智能写手 · 03-12
艾美疫苗盘中异动 股价大涨5.08%报8.280港元
公司概况
公司名称:
艾美疫苗
所属市场:
SEHK
上市日期:
--
主营业务:
艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。该公司的产品主要包括重组乙型肝炎疫苗、人用狂犬病疫苗、甲型肝炎灭活疫苗、腮腺炎疫苗、肾综合征出血热灭活疫苗和MPSV4。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。该公司的在研疫苗包括信使核糖核酸(mRNA)新冠(COVID-19)疫苗、灭活新冠疫苗、广谱新冠疫苗、PCV13、PPSV23及MCV4。该公司主要在国内市场开展业务。
发行价格:
--
{"stockData":{"symbol":"06660","market":"HK","secType":"STK","nameCN":"艾美疫苗","latestPrice":8.13,"timestamp":1711613283021,"preClose":8.01,"halted":0,"volume":274600,"delay":0,"floatShares":492173711,"shares":1211062599,"eps":-0.28656933,"marketStatus":"耶稣受难节休市","marketStatusCode":7,"change":0.12,"latestTime":"03-28 16:08:03","open":8.15,"high":8.3,"low":7.97,"amount":2218656,"amplitude":0.041199,"askPrice":8.13,"askSize":4000,"bidPrice":8.05,"bidSize":5600,"shortable":3,"etf":0,"ttmEps":-0.4739405985287212,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1712021400000},"adr":0,"listingDate":1664985600000,"adjPreClose":8.01,"openAndCloseTimeList":[[1711589400000,1711598400000],[1711602000000,1711612800000]],"volumeRatio":0.7139885598208483,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06660/wiki","defaultTab":"wiki","newsList":[{"id":"2422135485","title":"艾美疫苗近年来研发投入呈高速增长态势 2024年三款重磅迭代升级疫苗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2422135485","media":"经济参考网","top":-1,"share":"https://www.laohu8.com/m/news/2422135485?lang=zh_cn&edition=full","pubTime":"2024-03-28 14:32","pubTimestamp":1711607520,"startTime":"0","endTime":"0","summary":"13价肺炎结合疫苗、无血清迭代狂犬疫苗、23价肺炎多糖疫苗等3款迭代升级产品,预计在2024年内申报上市。年报显示,艾美疫苗2023年业绩亏损,主要原因是受新冠疫情变化影响,公司计提无形资产和商誉减值。2024年,艾美疫苗有3款疫苗申报上市,7款疫苗申报临床,公司产品已打开国际市场大门,出海步伐正在加速。高效研发彰显创新底气在业绩公告发布的同时,艾美疫苗还公告了多款迭代升级疫苗的研发进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281436298b6c9019&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281436298b6c9019&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422049609","title":"艾美疫苗(06660.HK)提交两项流感疫苗临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422049609","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2422049609?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:28","pubTimestamp":1711592880,"startTime":"0","endTime":"0","summary":"艾美疫苗(06660.HK) 公布,已于昨日(27日)提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请,且已于2月9日提交吸附破伤风疫苗的临床试验预申请。上述两款疫苗的研发符合公司产品研发战略布局,是实现公司研发多联多价产品的重要一步,将进一步完善公司的产品梯队。此外,集团已于昨日提交四价MDCK细胞流感病毒疫苗的临床试验预申请。目前,国内上市的流感疫苗均基于鸡胚工艺生产,尚无基于细胞基质的流感疫苗获批上市。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-27 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220923085721595_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220923085721595_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1338153/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2422390479","title":"艾美疫苗(06660):2023年业绩超预期,多款疫苗即将申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2422390479","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2422390479?lang=zh_cn&edition=full","pubTime":"2024-03-28 09:13","pubTimestamp":1711588425,"startTime":"0","endTime":"0","summary":"快讯正文艾美疫苗进入密集申报大年,mRNA技术平台布局多个爆款疫苗艾美疫苗近日发布2023年业绩及多个重磅新品研发公告。据公告显示,该公司2023年研发费用超过6.36亿元,同比增长27.2%,并有多款疫苗产品即将申报上市。根据年报数据,艾美疫苗已获得14个临床批件,并开展了21项临床试验。艾美疫苗目前已经商业化八款疫苗产品,其中,汉逊酵母重组乙型肝炎疫苗及Vero细胞冻干人用狂犬病疫苗在市场上处于领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281036248b6bb544&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281036248b6bb544&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422839977","title":"艾美疫苗今年三款重磅迭代升级疫苗申报上市,国际市场布局业已展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2422839977","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2422839977?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:24","pubTimestamp":1711585469,"startTime":"0","endTime":"0","summary":"艾美疫苗今日公布2023财年业绩报告,期内研发费用超6.36亿元,同比增长27.2%,今年3款重磅迭代升级疫苗申报上市,7款申报临床。截至2023年底,艾美取得了14个临床批件,开展了21项临床试验,5个处于III期临床收尾阶段。目前,13价肺炎结合疫苗、无血清迭代狂犬疫苗、23价肺炎多糖疫苗等3款重磅迭代升级疫苗,今年完成上市申报,有望尽快为公司业绩带来大幅增长。公司已上市的甲肝疫苗、乙肝疫苗和狂犬疫苗都是国际市场青睐的品种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280838188b6b7059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280838188b6b7059&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422971118","title":"艾美疫苗(06660):四价MDCK细胞流感病毒疫苗提交临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422971118","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422971118?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:13","pubTimestamp":1711584787,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 发布公告,该集团已于2024年3月27日提交四价MDCK细胞流感病毒疫苗的临床试验预申请。目前,国内上市的流感疫苗均基于鸡胚工艺生产,尚无基于细胞基质的流感疫苗获批上市。此外,公司研发的MDCK细胞流感疫苗,在传代过程中病毒突变几率低,不含卵清蛋白,过敏风险显著降低。接种流感疫苗是预防流感疾病及流感大爆发最经济、有效的措施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094334.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422971430","title":"艾美疫苗(06660)已提交b型流感嗜血杆菌(Hib)结合疫苗的临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422971430","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422971430?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:12","pubTimestamp":1711584724,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 公布,该集团已于2024年3月27日提交b型流感嗜血杆菌结合疫苗的临床试验预申请,且已于2024年2月9日提交吸附破伤风疫苗的临床试验预申请。此外,集团正在积极推进吸附无细胞百白破b型流感嗜血杆菌联合疫苗的研发,预计从2024年开始会陆续提交多联疫苗及其各组分疫苗的临床试验申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094335.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422979068","title":"艾美疫苗(06660)进入密集申报大年,mRNA技术平台布局多个爆款疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2422979068","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422979068?lang=zh_cn&edition=full","pubTime":"2024-03-28 08:04","pubTimestamp":1711584253,"startTime":"0","endTime":"0","summary":"艾美疫苗目前已经商业化八款疫苗产品,其中,汉逊酵母重组乙型肝炎疫苗及Vero细胞冻干人用狂犬病疫苗在市场上处于领先地位。值得关注的是,公司布局的mRNA疫苗技术平台及产品居于行业领先地位,上万例受试者的临床试验数据已充分验证了该平台产品的安全性和有效性,多款热门重磅大单品疫苗已在加速推进。未来,艾美疫苗将在此基础上持续推动mRNA疫苗创新,重点关注核心疾病领域中未被满足的临床需求,进一步提升核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1094330.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422661387","title":"艾美疫苗(06660):新型工艺高效价人二倍体狂犬病疫苗提交临床试验预申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2422661387","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422661387?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:23","pubTimestamp":1711459436,"startTime":"0","endTime":"0","summary":"智通财经APP讯,艾美疫苗 发布公告,集团已于2024年3月24日提交新型工艺高效价人二倍体狂犬病疫苗的临床试验预申请。集团已建设完成具备生产能力且满足国际化标准的新型工艺高效价人二倍体狂犬病疫苗车间,并正在进行设备调试和验证工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1092788.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421906192","title":"艾美疫苗(06660)上涨5.04%,报8.96元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421906192","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421906192?lang=zh_cn&edition=full","pubTime":"2024-03-21 15:36","pubTimestamp":1711006614,"startTime":"0","endTime":"0","summary":"3月21日,艾美疫苗(06660)盘中上涨5.04%,截至15:36,报8.96元/股,成交448.32万元。艾美疫苗股份有限公司是中国第二大疫苗供应商,涵盖了从研发到制造、再到商业化的整个价值链,并在全球范围内拥有五种经过验证的人用疫苗平台技术。2021年销售收入市场份额为2.1%,批签发量在所有民营疫苗公司中处于领先地位,同时也是中国首批获得P3实验室建设许可的疫苗企业之一。截至2023年中报,艾美疫苗营业总收入5.4亿元、净利润-2.5亿元。3月27日,艾美疫苗将披露2023财年年报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/21153639938188.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421206110","title":"艾美疫苗盘中异动 股价大涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421206110","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421206110?lang=zh_cn&edition=full","pubTime":"2024-03-21 15:36","pubTimestamp":1711006608,"startTime":"0","endTime":"0","summary":"2024年03月21日临近收盘15时36分,艾美疫苗股票出现波动,股价快速上涨5.29%。截至发稿,该股报8.981港元/股,成交量52.02万股,换手率0.11%,振幅7.62%。艾美疫苗股票所在的药品行业中,整体跌幅为0.04%。其相关个股中,中生联合、励晶太平洋、艾美疫苗涨幅较大,振幅较大的相关个股有中生联合、泰凌医药、三爱健康集团,振幅分别为15.38%、11.11%、10.20%。艾美疫苗公司简介:艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032115364887e7aad4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032115364887e7aad4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420211552","title":"艾美疫苗03月19日获主力加仓117万元 环比增加408.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420211552","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420211552?lang=zh_cn&edition=full","pubTime":"2024-03-19 16:16","pubTimestamp":1710836177,"startTime":"0","endTime":"0","summary":"03月19日, 艾美疫苗股价涨2.93%,报收8.77元,成交金额993万元,换手率0.23%,振幅5.16%,量比1.10。艾美疫苗今日主力资金净流入117万元,连续6日净流入,上一交易日主力净流入23万元,今日环比增加408.70%。该股近5个交易日上涨3.79%,主力资金累计净流入328万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入580万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031916165487973042&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031916165487973042&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420441418","title":"艾美疫苗03月18日主力资金流入23万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2420441418","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420441418?lang=zh_cn&edition=full","pubTime":"2024-03-18 16:15","pubTimestamp":1710749706,"startTime":"0","endTime":"0","summary":"03月18日, 艾美疫苗股价涨0.95%,报收8.52元,成交金额452万元,换手率0.11%,振幅3.44%,量比0.54。艾美疫苗今日主力资金净流入23万元,连续5日净流入,上一交易日主力净流入42万元,今日环比减少45.24%。该股近5个交易日上涨8.12%,主力资金累计净流入322万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入462万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318161512879228ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240318161512879228ad&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419411919","title":"艾美疫苗(06660.HK)3月27日举行董事会会议考虑及批准年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2419411919","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2419411919?lang=zh_cn&edition=full","pubTime":"2024-03-15 16:39","pubTimestamp":1710491953,"startTime":"0","endTime":"0","summary":"格隆汇3月15日丨艾美疫苗(06660.HK)宣布,董事会会议将于2024年3月27日(星期三)举行,藉以(其中包括)考虑及批准公司及其附属公司截至2023年12月31日止年度的年度业绩及其发布,并考虑建议派发末期股息(如有),以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151641058b36b650&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403151641058b36b650&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419629228","title":"艾美疫苗03月14日获主力加仓132万元 环比增加1100.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2419629228","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2419629228?lang=zh_cn&edition=full","pubTime":"2024-03-14 16:16","pubTimestamp":1710404207,"startTime":"0","endTime":"0","summary":"03月14日, 艾美疫苗股价涨3.29%,报收8.48元,成交金额1039万元,换手率0.25%,振幅4.51%,量比1.21。艾美疫苗今日主力资金净流入132万元,连续3日净流入,上一交易日主力净流入11万元,今日环比增加1100.00%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为50.00%,平均涨幅为4.78%。该股近5个交易日上涨15.71%,主力资金累计净流入368万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入395万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403141617588780ac9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403141617588780ac9d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2419954242","title":"艾美疫苗(06660)下跌5.33%,报8.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2419954242","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2419954242?lang=zh_cn&edition=full","pubTime":"2024-03-13 11:48","pubTimestamp":1710301710,"startTime":"0","endTime":"0","summary":"3月13日,艾美疫苗(06660)盘中下跌5.33%,截至11:48,报8.0元/股,成交353.9万元。艾美疫苗股份有限公司是中国第二大疫苗供应商,涵盖了从研发到制造、再到商业化的整个价值链,并在全球范围内拥有五种经过验证的人用疫苗平台技术。2021年销售收入市场份额为2.1%,批签发量在所有民营疫苗公司中处于领先地位,同时也是中国首批获得P3实验室建设许可的疫苗企业之一。截至2023年中报,艾美疫苗营业总收入5.4亿元、净利润-2.5亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/03/13114839832012.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2418732386","title":"艾美疫苗盘中异动 股价大涨5.08%报8.280港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2418732386","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2418732386?lang=zh_cn&edition=full","pubTime":"2024-03-12 09:45","pubTimestamp":1710207917,"startTime":"0","endTime":"0","summary":"2024年03月12日早盘09时45分,艾美疫苗股票出现异动,股价快速上涨5.08%。截至发稿,该股报8.280港元/股,成交量24.64万股,换手率0.05%,振幅3.81%。资金方面,该股资金流入149.035万港元,流出2.6212万港元。机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。艾美疫苗股票所在的药品行业中,整体涨幅为0.10%。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031209451779198728&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024031209451779198728&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aimbio.com","stockEarnings":[{"period":"1week","weight":-0.0568},{"period":"1month","weight":0.1817},{"period":"3month","weight":0.0357},{"period":"6month","weight":-0.7182},{"period":"1year","weight":-0.8036},{"period":"ytd","weight":0.0357}],"compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0149},{"period":"3month","weight":-0.0297},{"period":"6month","weight":-0.0712},{"period":"1year","weight":-0.1808},{"period":"ytd","weight":-0.0297}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"艾美疫苗股份有限公司是一家主要从事疫苗研发、制造和销售的中国公司。该公司的产品主要包括重组乙型肝炎疫苗、人用狂犬病疫苗、甲型肝炎灭活疫苗、腮腺炎疫苗、肾综合征出血热灭活疫苗和MPSV4。该公司的产品主要用于治疗乙肝、甲肝、腮腺炎、肾综合征出血热、狂犬病和脑膜炎球菌病。该公司的在研疫苗包括信使核糖核酸(mRNA)新冠(COVID-19)疫苗、灭活新冠疫苗、广谱新冠疫苗、PCV13、PPSV23及MCV4。该公司主要在国内市场开展业务。","exchange":"SEHK","name":"艾美疫苗","nameEN":"AIM VACCINE"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾美疫苗,06660,艾美疫苗股票,艾美疫苗股票老虎,艾美疫苗股票老虎国际,艾美疫苗行情,艾美疫苗股票行情,艾美疫苗股价,艾美疫苗股市,艾美疫苗股票价格,艾美疫苗股票交易,艾美疫苗股票购买,艾美疫苗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾美疫苗(06660)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾美疫苗(06660)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}